Shilpa Medicare is currently trading at Rs.270.45, up by 24.30 points or 9.87% from its previous closing of Rs. 246.15 on the BSE.
The scrip opened at Rs. 253.00 and has touched a high and low of Rs. 274.50 and Rs. 253.00 respectively. So far 538610 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 438.00 on 20-Jul-2022 and a 52 week low of Rs. 222.40 on 28-Mar-2023.
Last one week high and low of the scrip stood at Rs. 275.70 and Rs. 245.00 respectively. The current market cap of the company is Rs. 2256.85 crore.
The promoters holding in the company stood at 50.01%, while Institutions and Non-Institutions held 14.28% and 35.71% respectively.
Shilpa Medicare’s wholly owned subsidiary -- Shilpa Biologicals (SBPL) has received the marketing authorization permission for its Adalimumab 40 mg/0.4mL injection in prefilled syringe (PFS), a biosimilar of adalimumab higher concentration formulation (100mg/mL) in India. This is used for the treatment of Rheumatoid Arthritis (moderate to severe active RA & severe active and progressive RA) for which the phase 3 clinical trial has been successfully completed in Q3 2022. This formulation will contribute to increased patient comfort based on reduced injection volume.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: